Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD

Video

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.

Ciltacabtagene autoleucel (cilta-cel) has continued to produce deep and durable responses in heavily-pretreated patients with multiple myeloma, as seen in data from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2

Data from the CARTITUDE-1 study were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021,, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.

Further data on cilta-cel, as an earlier line of therapy in patients with only 1 to 3 prior lines of therapy, were also presented at ASH 2021. These data were from the CARTITUDE-2 study (NCT04133636), which found that progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4).

CGTLive spoke with Martin to learn more about cilta-cel. He discussed safety signals seen in the CARTITUDE-1 study, including the development of secondary hematologic malignancies. He also discussed future research that needs to be done with cilta-cel, including targeting selections and determining its place in the treatment landscape of multiple myeloma.

REFERENCES
1. New data from CARTITUDE-1 Study show continued deep and durable responses of ciltacabtageneautoleucel (cilta-cel) in treatment of heavily pretreated patients with multiple myeloma. News release. Janssen. December 12, 2021. https://www.janssen.com/new-data-cartitude-1-study-show-continued-deep-and-durable-responses-ciltacabtagene-autoleucel-cilta
2. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2 study of CiltacabtageneAutoleucel, a B-cell maturation antigen–Directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 549.
3. Cohen YC, Cohen DA, Delforge M, et al. Efficacy and safety of ciltacabtageneautoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: Updated results from CARTITUDE-2. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 3866.
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.